AI Article Synopsis
- - This study evaluates the levels of anti-TNFα drugs in patients with rheumatoid arthritis (RA) compared to those with spondyloarthritis (SpA), aiming to understand how treatment can be adjusted based on these levels.
- - A retrospective analysis was conducted on patients using infliximab, adalimumab, and etanercept, measuring drug levels and the presence of anti-drug antibodies through the ELISA technique.
- - The findings revealed that while drug levels varied among different medications and were influenced by the use of DMARDs, they remained unaffected by the overall activity of the diseases being treated.
Article Abstract
Background And Objectives: Knowledge of the levels of anti-TNFa drugs can modify treatment in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA).
Objectives: To compare the levels of anti-TNFa in patients with RA vs SpA, in different clinical situations.
Materials And Methods: A retrospective, observational study was conducted. Levels of anti-TNFa and the presence of anti-drug antibodies were measured in consecutively selected patients, using the ELISA technique.
Results: Fifty-three, 73 and 78 patients treated with infliximab, adalimumab and etanercept were studied, respectively. The median drug levels in patients using standard doses were infliximab 2.2 µg/mL (1.4-5.2), adalimumab 4.9 µg/mL (0.8-8.9) and etanercept 3.1 µg/mL (2.3-4.4). There were no differences in drug levels according to disease activity but we found differences in etanercept and infliximab levels according to DMARD use.
Conclusions: Levels of anti-TNFa drugs will change with DMARD treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.reumae.2021.06.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!